Application 203975

Type
NDA
Sponsor
GLAXOSMITHKLINE

Application Products#

Product, Drug, Ingredient table
ProductDrugIngredientFormStrengthReference drugReference standard
001ANORO ELLIPTAUMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATEPOWDER;INHALATIONEQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INHYesYes

Source provenance: Browse the complete Orange Book source catalog · source snapshot 1.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N203975-001ANORO ELLIPTAUMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATEEQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INHPOWDER / INHALATIONRLD, RS2013-12-18

Orange Book patents#

Current patent rows page 1 of 1 · 6 matching rows.

Application-product, Patent, Expiration table
Application-productPatentExpirationUse codeCoverage / statusSubmission date
N203975-00185113042027-06-14U-1476Drug product2014-01-09
N203975-0018511304*PED2027-12-14Pediatric extension
N203975-00174888272027-12-18Drug substance, Drug product2014-01-09
N203975-001110902942030-11-29U-32032021-09-14
N203975-001123969862030-11-29Drug product2025-09-19
N203975-00197507262030-11-29Drug product2017-09-21

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-08-01 22:54:322026-06N203975-001ANORO ELLIPTAEQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INHPOWDER / INHALATIONRLD, RS2013-12-18a50c72e98297…

Observed Orange Book patent history#

Captured, Edition, Application-product table
CapturedEditionApplication-productPatentExpirationUse codeCoverage / statusSubmission dateSource SHA-256
2026-08-01 22:54:322026-06N203975-00185113042027-06-14U-1476Drug product2014-01-09a50c72e98297…
2026-08-01 22:54:322026-06N203975-0018511304*PED2027-12-14Pediatric extensiona50c72e98297…
2026-08-01 22:54:322026-06N203975-00174888272027-12-18Drug substance, Drug product2014-01-09a50c72e98297…
2026-08-01 22:54:322026-06N203975-001110902942030-11-29U-32032021-09-14a50c72e98297…
2026-08-01 22:54:322026-06N203975-001123969862030-11-29Drug product2025-09-19a50c72e98297…
2026-08-01 22:54:322026-06N203975-00197507262030-11-29Drug product2017-09-21a50c72e98297…

openFDA label cross-check#

Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.

Matched openFDA labels page 1 of 1 · 2 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Umeclidinium and Vilanterol ElliptaUMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATEPrasco Laboratories6de414b1-f707-4b98-9e4b-742032ec90af2024-11-22Warnings, Adverse reactionsExact identifier
application applno (NDA): 203975
application number: NDA203975
Anoro ElliptaUMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATEGlaxoSmithKline LLC2dbd0671-c565-40c5-bf0f-e324db26799c2023-06-02Warnings, Adverse reactionsExact identifier
application applno (NDA): 203975
application number: NDA203975
ndc (product): 0173-0869

NDC Listings For This Application#

NDC listings for this application page 1 of 1 · 10 matching rows.

NDC, Name, Nonproprietary name table
NDCNameNonproprietary nameLabelerMarketing categoryStatus
0173-0869Anoro Elliptaumeclidinium bromide and vilanterol trifenatateGlaxoSmithKline LLCNDACurrent
0173-0869Anoro Elliptaumeclidinium bromide and vilanterol trifenatateGlaxoSmithKline LLCNDACurrent
0173-0869Anoro Elliptaumeclidinium bromide and vilanterol trifenatateGlaxoSmithKline LLCNDACurrent
0173-0869Anoro Elliptaumeclidinium bromide and vilanterol trifenatateGlaxoSmithKline LLCNDACurrent
0173-0869Anoro Elliptaumeclidinium bromide and vilanterol trifenatateGlaxoSmithKline LLCNDACurrent
0173-0869Anoro Elliptaumeclidinium bromide and vilanterol trifenatateGlaxoSmithKline LLCNDACurrent
0173-0869Anoro Elliptaumeclidinium bromide and vilanterol trifenatateGlaxoSmithKline LLCNDACurrent
0173-0869Anoro Elliptaumeclidinium bromide and vilanterol trifenatateGlaxoSmithKline LLCNDACurrent
0173-0869Anoro Elliptaumeclidinium bromide and vilanterol trifenatateGlaxoSmithKline LLCNDACurrent
0173-0869Anoro Elliptaumeclidinium bromide and vilanterol trifenatateGlaxoSmithKline LLCNDACurrent

Documents#

Document, Submission type, Date table
DocumentSubmission typeDate
74431SUPPL 2023-06-05
74430SUPPL 2023-06-05
72447SUPPL2022-10-21
72443SUPPL2022-10-21
59172SUPPL2019-06-26
59169SUPPL2019-06-25
58947SUPPL2019-06-04
58887SUPPL2019-05-30
50118SUPPL2017-10-19
50099SUPPL2017-10-19
47680SUPPL2017-03-24
47657SUPPL2017-03-23
47656SUPPL2017-03-23
40333SUPPL2016-02-26
10262SUPPL2016-02-26
43449ORIG2014-01-06
24454ORIG2014-01-06
32484ORIG2013-12-20
40332ORIG2013-12-19